<div id="readability-page-1"><p>Hendley &amp; Co. Inc. raised its stake in  Stryker Corporation (NYSE:SYK - Free Report) by 60.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,018 shares of the medical technology company's stock after purchasing an additional 5,274 shares during the quarter. Stryker comprises about  1.9% of Hendley &amp; Co. Inc.'s investment portfolio, making the stock its 18th biggest position. Hendley &amp; Co. Inc.'s holdings in Stryker were worth $5,546,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>If You Could Only Hold 3 Investments for Life, Consider These</li></ul><p>Other hedge funds also recently added to or reduced their stakes in the company. Mogy Joel R Investment Counsel Inc. raised its position in  Stryker by 3.4% in the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock valued at $36,561,000 after purchasing an additional 3,218 shares during the period.  Ferguson Wellman Capital Management Inc. raised its position in  Stryker by 1.9% in the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after purchasing an additional 3,341 shares during the period.  Harbor Capital Advisors Inc. purchased a new position in  Stryker in the first quarter valued at about $1,840,000.  Mar Vista Investment Partners LLC increased its position in shares of  Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after acquiring an additional 8,353 shares during the last quarter.  Finally, United Services Automobile Association purchased a new stake in shares of  Stryker during the first quarter worth about $2,857,000. 77.09% of the stock is owned by hedge funds and other institutional investors. </p><h2>Stryker Stock Up 0.8%</h2><p>Shares of Stryker stock opened at $369.14 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a market cap of $141.12 billion, a P/E ratio of 48.89, a P/E/G ratio of 2.64 and a beta of 0.94. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The business has a 50-day moving average price of $381.50 and a 200 day moving average price of $378.86. </p><ul><li>3 Stocks Helping to Bring AI to Healthcare</li></ul><p>Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker's quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.81 earnings per share.  Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, sell-side analysts forecast that  Stryker Corporation will post 13.47 earnings per share for the current fiscal year. </p><h2>Stryker Announces Dividend</h2><p>The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's payout ratio is presently 44.50%. </p><h2>Analysts Set New Price Targets</h2><ul><li>Boston Scientific: Why This MedTech Giant Isn’t Slowing Down</li></ul><p>A number of brokerages have recently issued reports on SYK. BTIG Research  reaffirmed a &#34;buy&#34; rating on shares of Stryker in a research report on Monday, July 14th. Redburn Partners  set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Weiss Ratings  reaffirmed a &#34;buy (b-)&#34; rating on shares of Stryker in a research report on Saturday, September 27th. Wells Fargo &amp; Company lifted their target price on Stryker from $435.00 to $445.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, August 1st. Finally, Rothschild Redb raised Stryker to a &#34;hold&#34; rating in a research report on Thursday, September 18th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned  a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $430.10.</p><p><b>Read Our Latest Research Report on Stryker</b></p><h2>Insider Buying and Selling</h2><p>In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own  5.20% of the company's stock. </p><h2>Stryker Profile</h2> (Free Report)<p>Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Stryker</li><li>How to trade using analyst ratings</li><li>EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector</li><li>3 Small Caps With Big Return Potential</li><li>These Are the 3 Hottest Sectors for Q3 Earnings Growth</li><li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li><li>AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal</li></ul><p><strong>Want to see what other hedge funds are holding SYK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Stryker Right Now?</h2><p>Before you consider Stryker, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Hendley & Co. Inc. increased its stake in Stryker Corporation (NYSE:SYK) by 60.3% in Q2, owning 14,018 shares valued at $5.55 million. Other hedge funds also adjusted their positions, with 77.09% of the stock held by institutional investors. Stryker's shares opened at $369.14, with a market cap of $141.12 billion. The company reported Q2 earnings of $3.13 per share, exceeding estimates, and announced a quarterly dividend of $0.84. Analysts maintain a "Moderate Buy" consensus with an average price target of $430.10.</p>

Stryker Corporation $SYK Shares Purchased by Hendley & Co. Inc.